NBIX logo

Neurocrine Biosciences (NBIX) Company Overview

Profile

Full Name:

Neurocrine Biosciences, Inc.

Sector:

Healthcare

Industry:

Drug Manufacturers - Specialty & Generic

Country:

United States

IPO:

May 23, 1996

Indexes:

Not included

Website:

http://www.neurocrine.com

Description:

Neurocrine Biosciences, Inc. is a commercial biopharmaceutical company specializing in the discovery and development of innovative treatments for patients with serious, complex, and poorly understood neurological, endocrine, and psychiatric disorders (endometriosis, tardive dyskinesia, uterine fibroids, essential tremor, classical congenital adrenal hyperplasia, epilepsy, Parkinson's disease, Friedrich's ataxia, etc.). The company was founded in January 1992 and reincorporated in the state of Delaware in May 1996. The headquarters are located in San Diego, California. Currently, Neurocrine is focused on the commercialization of INGREZZA - a treatment for adults with tardive dyskinesia. In April 2017, it received FDA approval and sales began in the United States.

Key Details

Price

$113.00

Market Cap

$11.27 B(Large cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$2.36 B(+24.81% YoY)

Annual EPS

$3.29(+33.20% YoY)

PE Ratio

34.35

Annual ROE

14.16%

Annual Debt To Equity

0.00

Beta

0.69

Events Calendar

Earnings

Next earnings date:

May 1, 2025

Recent quarterly earnings:

Feb 6, 2025

Recent annual earnings:

Feb 6, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 24, 25 HC Wainwright & Co.
Buy
Feb 21, 25 HC Wainwright & Co.
Buy
Feb 10, 25 HC Wainwright & Co.
Buy
Feb 10, 25 Guggenheim
Buy
Feb 7, 25 Wedbush
Outperform
Feb 7, 25 RBC Capital
Sector Perform
Feb 7, 25 Needham
Hold
Feb 7, 25 HC Wainwright & Co.
Buy
Feb 7, 25 Canaccord Genuity
Buy
Feb 7, 25 B of A Securities
Buy

Screeners with NBIX included

Growing Shares Outstanding
US stocks
High Piotroski score stocks
Stocks below SMA 200
Most recommended stocks
Best performing stocks last 5 years
Stocks below analysts price target
Healthcare sector
All stocks
High Altman Z score stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$113.00
NBIX price is $113.00

Price All-time High

$155.00
NBIX price is currently -27.10% below its historical high of $155.00

Price Analysts Target

$163.00
NBIX price is currently -30.67% lower than the consensus analysts' forecast

Price Most Recent Change

+0.3%
NBIX price was up +0.3% on Mar 8, 2025

Price YTD Change

-16.32%
NBIX price is down -16.32% since January 1st

Price 3-Year Change

+28.48%
NBIX price is up +28.48% over the past 3 years

Market cap

Market Cap

$11.27 B
NBIX market capitalization is $11.27 billion

Market Cap 3-Year Change

+34.5%
NBIX market capitalization is up +34.5% over the past 3 years

Market Cap All-time High

$15.65 B
NBIX market capitalization is currently -28.02% below its historical high of $15.65 billion

Market Cap Sector Rank

93%
NBIX market capitalization is higher than 93% of companies in Healthcare sector

Technical

Beta

0.69
NBIX beta is 0.69

200-day SMA

$131.58
NBIX price is currently -14.12% below its 200-day simple moving average

14-day RSI

32.16
NBIX 14-day relative strength index is 32.16

30-day Relative Volume

1.07
NBIX 30-day relative volume is 1.07

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$2.36 B
NBIX annual revenue is $2.36 billion

Annual Revenue Analysts Estimate

$2.68 B
NBIX annual revenue is currently -12.02% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+24.81%
NBIX annual revenue is up +24.81% year-on-year

Annual Revenue Sector Rank

86.07%
NBIX annual revenue is higher than 86.07% of companies in Healthcare sector

Profit

Annual Gross Profit

$2.32 B
NBIX annual gross profit is $2.32 billion

Annual Gross Margin

98.56%
NBIX annual gross profit margin is 98.56%

Annual Operating Profit

$583.00 M
NBIX annual operating income is $583.00 million

Annual Operating Margin

24.75%
NBIX annual operating profit margin is 24.75%

Annual Net Income

$341.30 M
NBIX annual net profit is $341.30 million

Annual Net Margin

14.49%
NBIX annual net profit margin is 14.49%

EPS

Annual EPS

$3.29
NBIX annual earnings per share is $3.29

Annual EPS Analysts Estimate

$6.36
NBIX annual earnings per share is currently -48.28% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

+33.2%
NBIX annual earnings per share is up +33.2% year-on-year

Annual EPS Sector Rank

94.08%
NBIX annual earnings per share is higher than 94.08% of companies in Healthcare sector

ROA & ROE

Annual ROA

9.79%
NBIX annual return on assets is 9.79%

Annual ROE

14.16%
NBIX annual return on equity is 14.16%

EBIT & EBITDA

Annual EBIT

$583.00 M
NBIX annual earnings before interest & taxes is $583.00 million

Annual EBITDA

$583.00 M
NBIX annual EBITDA is $583.00 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

34.35
NBIX price to earnings ratio is 34.35

PE Ratio Sector Rank

64.04%
NBIX price to earnings ratio is higher than 64.04% of companies in Healthcare sector

PB Ratio

PB Ratio

4.35
NBIX price to book ratio is 4.35

PB Ratio Sector Rank

79.9%
NBIX price to book ratio is higher than 79.9% of companies in Healthcare sector

PS Ratio

PS Ratio

4.78
NBIX price to sales ratio is 4.78

PS Ratio Sector Rank

62.32%
NBIX price to sales ratio is higher than 62.32% of companies in Healthcare sector

Enterprise value

Enterprise Value

$11.49 B
NBIX enterprise value is $11.49 billion

Enterprise Value Sector Rank

92.12%
NBIX enterprise value is higher than 92.12% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

18.46
NBIX EV/EBITDA is 18.46

EV/EBITDA Sector Rank

89.58%
NBIX EV/EBITDA is higher than 89.58% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

3.40
NBIX annual current ratio is 3.40

Annual Quick Ratio

3.28
NBIX annual quick ratio is 3.28

Leverage

Annual Debt To Equity

0.00
NBIX annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

4.61
NBIX annual interest coverage ratio is 4.61

Risk & Stability

Piotroski F-Score

6
NBIX piotroski f-score is 6

Altman Z-Score

7.54
NBIX altman z-score is 7.54

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$3.72 B
NBIX annual total assets is $3.72 billion

Annual Non Current Assets

$1.99 B
NBIX annual long term assets is $1.99 billion

Annual Current Assets

$1.72 B
NBIX annual total current assets is $1.72 billion

Annual Cash & Cash Equivalents

$233.00 M
NBIX annual cash & cash equivalents is $233.00 million

Equity

Annual Book Value

$2.59 B
NBIX annual book value is $2.59 billion

Annual Working Capital

$1.22 B
NBIX annual working capital is $1.22 billion

Liabilities

Annual Total Liabilities

$1.13 B
NBIX annual total liabilities is $1.13 billion

Annual Total Long Term Liabilities

$621.30 M
NBIX annual total long term liabilities is $621.30 million

Annual Current Liabilities

$507.70 M
NBIX annual total current liabilities is $507.70 million

Annual Accounts Payable

$110.00 M
NBIX annual accounts payable is $110.00 million

Debt

Annual Total Debt

$455.10 M
NBIX annual total debt is $455.10 million

Annual Total Debt 1-Year Change

+6.23%
NBIX annual total debt is up +6.23% year-on-year

Annual Long Term Debt

$455.10 M
NBIX annual long term debt is $455.10 million

Annual Short Term Debt

-
NBIX annual short term debt value is unknown

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$1.77 B
NBIX annual total expenses is $1.77 billion

Annual Operating Expenses

$1.74 B
NBIX annual total operating expenses is $1.74 billion

Annual Cost Of Goods Sold

$34.00 M
NBIX annual cost of goods sold is $34.00 million

Annual SGA

$1.01 B
NBIX annual SGA is $1.01 billion

Annual D&A

$27.10 M
NBIX annual depreciation & amortization is $27.10 million

Annual Interest Expense

$126.60 M
NBIX annual interest expense is $126.60 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

$595.40 M
NBIX annual cash flow from operations is $595.40 million

Annual CFO 1-Year Change

+52.71%
NBIX annual cash flow from operations is up +52.71% year-on-year

Annual CFI

-$126.80 M
NBIX annual cash flow from investing activities is -$126.80 million

Annual CFI 1-Year Change

+72.85%
NBIX annual cash flow from investing activities is up +72.85% year-on-year

Annual CFF

-$486.70 M
NBIX annual cash flow from financing activities is -$486.70 million

Annual CFF 1-Year Change

-845.33%
NBIX annual cash flow from financing activities is down -845.33% year-on-year

Free CashFlow

Annual FCF

$557.20 M
NBIX annual free cash flow is $557.20 million

Annual FCF 1-Year Change

+54.09%
NBIX annual free cash flow is up +54.09% year-on-year

CAPEX

Annual CAPEX

$38.20 M
NBIX annual capital expenditures is $38.20 million

Annual CAPEX 1-Year Change

+34.98%
NBIX annual capital expenditures is up +34.98% year-on-year

Institutional Ownership

Similar stocks

COR logo
Cencora (COR)
UHS logo
Universal Health Services (UHS)
DVA logo
DaVita (DVA)
VTRS logo
Viatris (VTRS)
EXEL logo
Exelixis (EXEL)
RDY logo
Dr Reddys Laboratories Limited (RDY)
PEN logo
Penumbra (PEN)
AVTR logo
Avantor (AVTR)
DOCS logo
Doximity (DOCS)

FAQ

  • What is the ticker symbol for Neurocrine Biosciences?
  • Does Neurocrine Biosciences pay dividends?
  • What sector is Neurocrine Biosciences in?
  • What industry is Neurocrine Biosciences in?
  • What country is Neurocrine Biosciences based in?
  • When did Neurocrine Biosciences go public?
  • Is Neurocrine Biosciences in the S&P 500?
  • Is Neurocrine Biosciences in the NASDAQ 100?
  • Is Neurocrine Biosciences in the Dow Jones?
  • When was Neurocrine Biosciences's last earnings report?
  • When does Neurocrine Biosciences report earnings?
  • Should I buy Neurocrine Biosciences stock now?

What is the ticker symbol for Neurocrine Biosciences?

The ticker symbol for Neurocrine Biosciences is NASDAQ:NBIX

Does Neurocrine Biosciences pay dividends?

No, Neurocrine Biosciences does not pay dividends

What sector is Neurocrine Biosciences in?

Neurocrine Biosciences is in the Healthcare sector

What industry is Neurocrine Biosciences in?

Neurocrine Biosciences is in the Drug Manufacturers - Specialty & Generic industry

What country is Neurocrine Biosciences based in?

Neurocrine Biosciences is headquartered in United States

When did Neurocrine Biosciences go public?

Neurocrine Biosciences's initial public offering (IPO) was on May 23, 1996

Is Neurocrine Biosciences in the S&P 500?

No, Neurocrine Biosciences is not included in the S&P 500 index

Is Neurocrine Biosciences in the NASDAQ 100?

No, Neurocrine Biosciences is not included in the NASDAQ 100 index

Is Neurocrine Biosciences in the Dow Jones?

No, Neurocrine Biosciences is not included in the Dow Jones index

When was Neurocrine Biosciences's last earnings report?

Neurocrine Biosciences's most recent earnings report was on Feb 6, 2025

When does Neurocrine Biosciences report earnings?

The next expected earnings date for Neurocrine Biosciences is May 1, 2025

Should I buy Neurocrine Biosciences stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions